N. I. Vavilov-the man and his work

A brief sketch is presented of Vavilov's career, his main contributions to science and personal qualities. The imporatnce of his work in genetics, agro-ecology, plant breeding, the experimental taxonomy of crop plants and genetic resources conservation is also emphasized.     

Ability of man to detect increases in his breathing.

The ability of four normal subjects to detect increases in their ventilation was studied at rest and at two levels of exercise using a raised inspired Pco2 to further increase ventilation. Subjects signaled when the increase in ventilation was recognized. The average tidal volume (VT) at rest was 520 ml with a frequency of 14; these values increased to an average of 3,300 ml and 21 at the highest work load. There was no significant change in frequency with CO2. Detection occurred when the tidal volume increased by 700 ml (varying 550-890 between subjects but constant for any one subject at the three levels of ventilation.) Thus the appreciation of increase is proportionately more sensitive at higher levels of ventilation. Experiments in which the ventilation was increased by hypoxia or by following a visual demand, and observations of other sensations (oral, cerebral) indicate that the increase in vetilation is recognized through increased breathing rather than awareness of ventilatory stimuli.     

Guardians at the gate

Product life cycle management, which necessarily utilizes a multi-disciplinary approach, is an essential tool for companies that develop or market therapeutic monoclonal antibodies (mAbs). Too little attention to such a plan, or use of the wrong resources, could substantially curtail a product’s life span. The most difficult part of the therapeutic antibody business is the development of high-quality, safe and effective products. Great care should thus be taken to ensure that products with these characteristics are positioned in a marketplace that is competition-free for as long as possible. In an era of mAbs with billion dollar markets, the loss of even a single day of sales could cost companies millions of dollars in lost revenue.     

Guardians at the gate

Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state of the law surrounding therapeutic antibodies will be explained, and important challenges to this technology area will be discussed. Much is at stake when companies market therapeutic monoclonal antibodies; therefore, a firm understanding of this important form of protection is critically important for anyone developing such products.     

Guardians at the gate

Patent protection and FDA exclusivities are the two principal forms of protection available to companies that develop therapeutic monoclonal antibodies. Proposed changes to both forms of protection are currently being debated in the United States Congress. Specifically, Congress is presently debating both biosimilar and patent reform legislations. Although no bill has yet passed, it is expected that patent reform legislation should pass this year. It is less likely that a biosimilar bill will pass this year. However, when legislations are enacted, the changes will significantly impact the business of therapeutic monoclonal antibodies.